A new combo for squamous lung cancer as first treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (SYHX2011) combined with two standard chemotherapy drugs and an immunotherapy drug as the first treatment for advanced squamous non-small cell lung cancer that cannot be removed by surgery or cured by radiation. It may be an option if your cancer has a PD-L1 level of at least 1% and no targetable gene mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced squamous non-small cell lung cancer that cannot be treated with surgery or radiation.
- Your cancer does not have certain gene changes (like EGFR, ALK, or ROS1).
- At least 1% of your cancer cells show PD-L1 protein.
- You have not had any previous cancer treatment for this stage of your disease.
- You are in good physical condition (able to care for yourself) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug combined with chemotherapy compared to a standard immunotherapy combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the new combination is more effective and may offer a new first-line treatment option.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.